PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $2.8 million, or $0.05 per share, for the third quarter ended September 30, 2011, compared with a net loss of $4.7 million, or $0.09 per share, for the comparable period in 2010.
For the quarter ended September 30, 2011, total operating costs and expenses were $2.9 million, compared with $4.7 million in the third quarter of 2010. Operating expenses in the 2011 third quarter included stock-based compensation expense of approximately $0.5 million. Operating expenses were approximately 39% lower in the third quarter of 2011 compared with the same period in 2010, primarily due to lower headcount, clinical development and facility expenses.
For the nine months ended September 30, 2011, Telik reported a net loss of $9.5 million, or $0.18 per share, compared with a net loss of $14.9 million, or $0.28 per share, for the same period in 2010. Total operating expenses for the first nine months of 2011 were $9.6 million, compared with $15.1 million for the same period in 2010. Operating expenses in the first nine months of 2011 included approximately $1.2 million in stock-based compensation expense. The reduction in operating expenses of approximately 37% in the first nine months of 2011 compared with the same period in 2010 was primarily due to lower headcount, reduced clinical trial expenses, lower stock-based compensation and lower facility costs.
At September 30, 2011, Telik had $14.0 million in cash, cash equivalents and investments including restricted investments, compared to $24.1 million at December 31, 2010.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2011201020112010Operating costs and expenses:Research and development
8,202General and administrative
1,5502,1015,0906,856Total operating costs and expenses
2,8554,6709,55415,058Loss from operations
(2,855)(4,670)(9,554)(15,058)Interest and other income (expense), net
(4,653)$ (9,523)$ (14,926)Basic and diluted net loss per share
(0.28)Weighted average shares used to calculate basic and diluted net loss per share
53,96253,55353,87053,514Selected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20112010Cash, cash equivalents, investments and restricted investments
|SOURCE Telik, Inc.|
Copyright©2010 PR Newswire.
All rights reserved